Aptose TUSCANY trial shows 86.2% CRc in newly diagnosed AML; all TP53-mut respond

Aptose Biosciences Inc.

Composite complete response (CRc) rate 86.2% in evaluable patients across all TUS+VEN+AZA dose groups.
MRD negativity rate 86.4% in patients achieving CR/CRh; 62.5% overall MRD negative among all dosed.
160mg cohort: 100% CR in 4 TP53-mutated patients with complex karyotype; 76.9% CRc across 13 patients.
No treatment-related deaths, QT prolongation, CPK elevations, or differentiation syndrome observed.
19 patients remain on treatment; 6 proceeded to stem cell transplantation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.